Go to the list of all blogs
Sergey Savastiouk's Avatar
published in Blogs
Oct 26, 2026
TickeronGET DAILY SIGNALS
Why Is Verastem Oncology (VSTM) Stock Down -6.27% Today?

Why Is Verastem Oncology (VSTM) Stock Down -6.27% Today?

Key Takeaways

  • VSTM shares fell 6.27% on Monday, pulling back to $9.41 from a prior close of $10.04.
  • The decline followed a sharp two-week rally, suggesting profit-taking rather than a fresh negative catalyst.
  • A roughly $250 million equity offering priced earlier in October remains an overhang from dilution concerns.
  • The move tracked broad softness in small-cap biotechnology amid elevated Treasury yields and risk-off sentiment.
  • Traders are now watching the next earnings report and further VS-7375 clinical updates for direction.
  • Explore Price Targets, Earnings, and Forecast pages for additional data on this ticker.
  • Discover active strategies in the Trending AI Robots section for current market conditions.

Opening Summary

Verastem Oncology, doing business as Verastem, Inc. (VSTM), is a commercial-stage biopharmaceutical company focused on RAS/MAPK pathway-driven cancers. Its portfolio includes the approved AVMAPKI FAKZYNJA CO-PACK for KRAS-mutated recurrent low-grade serous ovarian cancer and the investigational KRAS G12D inhibitor VS-7375. In Monday's session, VSTM shares declined 6.27%, or $0.63, to $9.41 from the prior session's closing price of $10.04. The pullback came after a powerful rally that had lifted the stock roughly 26% over the preceding two weeks, with no single company-specific headline driving the day's decline.

Profit-Taking After a Sharp Rally

The most immediate driver of Monday's move appears to be profit-taking following an outsized run. VSTM surged roughly 20% in a single session in mid-October—its best day in nearly a year—after the company reported encouraging early data for VS-7375 across pancreatic, lung, and colorectal cancers and announced alignment with the U.S. Food and Drug Administration on a late-stage trial path. Multiple analysts responded by raising price targets, extending the momentum into the following week. After such a steep climb, a consolidation phase is common as short-term traders lock in gains and momentum cools.

Equity Offering and Dilution Overhang

Adding to the selling pressure is the lingering effect of the company's recent capital raise. In mid-October, VSTM priced a public offering of common stock and pre-funded warrants expected to generate roughly $250 million in gross proceeds at $8.00 per share to fund VS-7375 development. While the raise strengthened the balance sheet and extended the cash runway, it also meaningfully increased the share count. For a small-cap biotech that remains unprofitable, the dilution from such financings can weigh on the stock as investors digest the larger float, even when the underlying clinical story is positive.

Broader Small-Cap Biotech Pressure

The decline also aligned with broader market conditions. Small-cap and development-stage biotechnology names have faced headwinds amid elevated Treasury yields and a generally more cautious risk appetite, which tend to pressure companies with negative cash flow and valuations tied to future milestones. Even as VSTM has outperformed over recent months, the sector-wide de-rating has made momentum-driven biotech shares more vulnerable to sharp, sudden pullbacks.

Market Context and Trading Activity

The pullback unfolded against the backdrop of the stock's strongest stretch of the year. From a 52-week low near $3.43, VSTM more than tripled to approach its 52-week high of $10.82, reflecting investor enthusiasm for the VS-7375 clinical program and commercial execution of its approved therapy. Monday's decline brought the stock back toward the mid-point of its recent range rather than signaling a breakdown of the broader uptrend. Volume remained active, consistent with elevated participation following the data-driven spike, while the move broadly mirrored weakness across biotechnology peers and small-cap indices.

What Comes Next for VSTM

Looking ahead, investors will focus on several near-term catalysts. The company's next quarterly earnings report is scheduled for early November, and commentary on AVMAPKI FAKZYNJA CO-PACK launch metrics and pipeline timelines will be closely scrutinized. Further VS-7375 data across pancreatic, lung, and colorectal cancers, along with progress on registration-directed Phase 2 trials and the planned Phase 3 program, remain the central drivers of the investment thesis. Risks include the competitive KRAS G12D landscape, clinical trial execution, potential additional financings, and a planned chief executive transition effective January 1, 2027. While the fundamental story remains intact, volatility is likely to persist as the market weighs these developments.

Trending AI Robots

Tickeron's Trending AI Robots page showcases a curated selection of the platform's strongest-performing AI trading bots under current market conditions. Tickeron offers hundreds of AI-powered trading bots covering thousands of tickers, with strategies that vary by approach, timeframe, performance metrics, and traded symbols. Only the top performers are featured in this section, giving traders a focused view of active strategies. Explore the Trending AI Robots page to see which strategies are leading right now.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: VSTM

Contributor

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.


VSTM sees MACD Histogram crosses below signal line

VSTM saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on November 04, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 40 instances where the indicator turned negative. In 38 of the 40 cases the stock moved lower in the days that followed. This puts the odds of a downward move at 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on November 05, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on VSTM as a result. In 71 of 84 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 85%.

VSTM moved below its 50-day moving average on November 12, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for VSTM crossed bearishly below the 50-day moving average on November 18, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 13 of 13 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where VSTM declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.

Bullish Trend Analysis

The RSI Indicator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 4 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a +4.48% 3-day Advance, the price is estimated to grow further. Considering data from situations where VSTM advanced for three days, in 204 of 249 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.

VSTM may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is 57 (best 1 - 100 worst), indicating steady price growth. VSTM’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of 82 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (15.237) is normal, around the industry mean (3.596). P/E Ratio (-3.447) is within average values for comparable stocks, (-1.186). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.158). Dividend Yield (0.000) settles around the average of (131.631) among similar stocks. P/S Ratio (7.446) is also within normal values, averaging (443.347).

The Tickeron PE Growth Rating for this company is 90 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. VSTM’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

Notable companies

The most notable companies in this group are Moderna (NASDAQ:MRNA), Regeneron Pharmaceuticals (NASDAQ:REGN), Incyte Corp (NASDAQ:INCY), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), Sarepta Therapeutics (NASDAQ:SRPT), Novavax (NASDAQ:NVAX), Nektar Therapeutics (NASDAQ:NKTR), Inovio Pharmaceuticals (NASDAQ:INO), Cel-Sci Corp (ASE:CVM).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.24B. The market cap for tickers in the group ranges from 58 to 138.67B. VRTX holds the highest valuation in this group at 138.67B. The lowest valued company is SEELQ at 58.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was -12%. For the same Industry, the average monthly price growth was -18%, and the average quarterly price growth was -28%. VIVS experienced the highest price growth at 105%, while CUE experienced the biggest fall at -74%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was 37%. For the same stocks of the Industry, the average monthly volume growth was 41% and the average quarterly volume growth was -10%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 44
Price Growth Rating: 69
SMR Rating: 93
Profit Risk Rating: 93
Seasonality Score: -3 (-100 ... +100)
AI Patterns 1
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a company that discovers and develops drugs

Industry Biotechnology

Industry
Biotechnology
Address
117 Kendrick Street
Phone
+1 781 292-4200
Employees
104
Web
https://www.verastem.com
Interact to see
Advertisement
The ADR gapped lower in premarket trading and was at $335.71 in early regular-session trading, -4.65% from Thursday's close of $352.09. The move extends a global AI and chip unwind: investors are cutting crowded semiconductor bets on stretched valuations, rising sector debt, data-center opposition and Nvidia's leadership turmoil, and Nvidia's strong quarter failed to calm sentiment.
Micron shares slid from Thursday's $690.44 close to $635.41, a -7.97% loss, deepening during Friday's regular session after an already soft premarket. The decline was sector-driven, not company-specific: investors kept unwinding AI exposure as Anthropic fell back after its debut, while hawkish Fed comments and doubts about Nvidia's leadership and AI spending returns pressured chip valuations.
Meta Platforms fell from a $596.22 previous close to $583.40, a -2.15% move, with the decline built in premarket trading and held through early Friday action after Thursday's -3.27% drop. The drop was sector-driven, not company-specific: Anthropic slid roughly -6% to -10% premarket on its second trading day, reviving doubts that AI spending will generate returns, and AI-linked megacaps sold off broadly with Nasdaq 100 futures down about -1.5%.
ANT dropped from Thursday's record-debut close of $97.17 to about $88.56 in Friday premarket trading, a -8.86% move ahead of the opening bell, still above its $83 IPO price. The decline came from a broad AI and technology selloff rather than any Anthropic-specific disclosure: Nvidia and AMD traded lower premarket, index futures were sharply down, and renewed doubts over AI spending and valuations drove profit-taking after the +17.07% first-day gain.
IREN dropped -8.33% to $13.21 from Thursday's $14.41 close, with weakness building in premarket and extending through the first hour of regular trading. The decline extends a sector-wide neocloud rout: Anthropic's post-IPO slide and turmoil at Nvidia revived doubts about debt-funded AI data center spending, dragging CoreWeave and Nebius down with it; no IREN-specific news was released.